<DOC>
	<DOCNO>NCT01710007</DOCNO>
	<brief_summary>1PC002 newly develop synthetic highly potent HMG-CoA reductase inhibitor . Its active compound , pitavastatin recently approve US FDA indication primary hypercholesterolemia combine dyslipidaemia . It exhibit unique pharmacokinetic property . Unlike atorvastatin metabolize CYP3A4 , metabolism 1PC002 depend CYP3A4 . This multi-center study conduct confirm efficacy safety 1PC002 administer 12 week non-inferior atorvastatin .</brief_summary>
	<brief_title>Efficacy Safety Study Pitavastatin Hypercholesterolemia</brief_title>
	<detailed_description>This prospective , active-controlled , double-blind , randomize , parallel , multi-center study . To target 150 evaluable subject , approximately 200 Taiwanese patient primary hypercholesterolemia combine dyslipidemia enrol study . After provide write inform consent , patient undergo complete physical examination , vital sign ( brachial BP / HR ) , medical history , lab assessment , include fast serum LDL-C , TC , HDL-C , TG , non-HDL . They take hypolipidemic drug least 4 week prior initiation study treatment . All eligible subject randomize 2 group 1:1 ratio receive either 2 mg 1PC002 10 mg atorvastatin daily 12 week . - Study Group : 1PC002 1 cap . q.d . p.o . - Control Group : Atorvastatin 1 cap . q.d . p.o . After enter baseline visit , lipid profile ( include fast serum LDL-C , TC , HDL-C , TG , non-HDL , Apo A1 , Apo B Apo B / Apo A1 ratio ) , hs-CRP , eGFR , spot urinary albumin / creatinine ratio ( ACR ) central BP value obtain baseline , Week 4 Week 12 evaluate effectiveness study drug possible change laboratory data . Non-HDL value calculate subtract HDL-C TC . Moreover , serum Cystatin C , another biomarker renal function , also assess baseline Week 12 . For monitor safety , biochemical hematological assessment perform baseline , Week 4 12 . Additional liver function CK test conduct Week 8 . The occur AE ( ) SAE follow resolution event consider stable .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>1 . Females male age 20 80 year . 2 . Subjects meet All following diagnosis screen visit : Primary hypercholesterolemia combine dyslipidemia TC ≥ 220 mg/dL LDLC ≥ 130 mg/dL TG &lt; 400 mg/dL 3 . Subjects willing able provide ICF . 1 . Females pregnant , breastfeed intent pregnant study period , childbearing potential use effective contraception . 2 . Subject document homozygous familial hypercholesterolemia . 3 . Subject document HIV . 4 . Subject document hypothyroidism inadequate treatment judge investigator . 5 . Subjects unstable cardiovascular disease ( CVD ) prior randomization . 6 . Subjects hepatic biliary disorder , acute hepatitis , acute exacerbation chronic hepatitis , liver cirrhosis , liver cancer jaundice . 7 . Any condition might significantly alter absorption , distribution , metabolism , excretion study drug . 8 . Subjects follow lab data screen visit : serum creatine kinase ( CK ) &gt; 5 x upper limit normal ( ULN ) ALT AST &gt; 3 x ULN serum creatinine ≥ 1.5 mg/dL HbA1c &gt; 8.0 % 9 . Subject follow past history : hypersensitivity statins ingredient study drug resistant statin treatment 10 . Use lipidlowering agent within 4 week prior initiation study treatment . 11 . Use investigational product within 4 week prior screen . 12 . Any unstable concomitant disease clinical condition , include presence laboratory abnormality , place subject unacceptable risk participate study confound ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>HMG-CoA reductase inhibitor</keyword>
</DOC>